[Characterizing of the NADH2-lipoamide dehydrogenase as tetrazolium reductase (author's transl)].
D000577:Amides; D000818:Animals; D001386:Azides / Q000494:pharmacology; D002729:Chloromercuribenzoates / Q000494:pharmacology; D003300:Copper / Q000494:pharmacology; D003486:Cyanides / Q000494:pharmacology; D008058:Dihydrolipoamide Dehydrogenase / Q000378:metabolism*; D004126:Dimethylformamide / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D006651:Histocytochemistry; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007700:Kinetics; D008628:Mercury / Q000494:pharmacology; D009206:Myocardium / Q000201:enzymology; D010084:Oxidation-Reduction; D010618:Phenanthrolines / Q000494:pharmacology; D013501:Surface-Active Agents; D013552:Swine; D013778:Tetrazolium Salts
D000577:Amides; D001386:Azides; D002729:Chloromercuribenzoates; D003486:Cyanides; D010618:Phenanthrolines; D013501:Surface-Active Agents; D013778:Tetrazolium Salts; D003300:Copper; D004126:Dimethylformamide; D004492:Edetic Acid; D008058:Dihydrolipoamide Dehydrogenase; D008628:Mercury
Charakterisierung der NADH2-Lipoamid-Dehydrogenase als Tetrazoliumreduktase